WO2017010515A1 - エストロゲン受容体α阻害作用を有するエストロゲン受容体βパーシャルアゴニスト及びこれを用いた婦人科疾患治療剤 - Google Patents
エストロゲン受容体α阻害作用を有するエストロゲン受容体βパーシャルアゴニスト及びこれを用いた婦人科疾患治療剤 Download PDFInfo
- Publication number
- WO2017010515A1 WO2017010515A1 PCT/JP2016/070687 JP2016070687W WO2017010515A1 WO 2017010515 A1 WO2017010515 A1 WO 2017010515A1 JP 2016070687 W JP2016070687 W JP 2016070687W WO 2017010515 A1 WO2017010515 A1 WO 2017010515A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- uterine
- estrogen receptor
- therapeutic agent
- endometriosis
- partial agonist
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
Definitions
- the present invention relates to an estrogen receptor ⁇ partial agonist having an estrogen receptor ⁇ inhibitory action and a gynecological disease therapeutic agent using the same.
- Organic gynecological diseases include diseases caused by abnormalities such as estrogen and progesterone. For example, endometriosis, uterine fibroids, uterine adenomyosis.
- gonadotropin agonists are known as pharmacological therapies, but the use period is limited due to side effects such as bone mineral loss and ovarian function deficiency. Since there are no long-term drugs for treating gynecological diseases, surgical treatment such as surgical resection is still the first choice.
- Tamoxifen registered trademark: Norbadex
- Japan has been used in Japan as an indication for breast cancer since the 1980s as a drug that antagonistically inhibits the binding of estrogen to the receptor.
- this drug itself causes endometrial cancer, uterine sarcoma or endometriosis, and is not used for the treatment of estrogen-dependent diseases including endometriosis.
- the mechanism of action of this drug on the endometrium is considered to have an intrinsic partial agonistic action on the estrogen receptor.
- Fulvestrant registered trademark: Fesodex
- this drug is said to show no intrinsic partial agonistic action on the estrogen receptor.
- this drug since this drug has a low gastrointestinal absorption rate and a short half-life even when administered intravenously, it must be administered in a high volume intramuscularly. Has been. Therefore, it is not used as an oral drug for the treatment of estrogen-dependent diseases.
- raloxifene registered trademark: Evista
- SERM selective estrogen receptor modulator
- this drug is a therapeutic agent for osteoporosis whose mechanism of action is the increase in bone mass due to the action of estrogen receptor partial agonist, and it is an estrogen-dependent disease such as endometriosis, uterine fibroid, uterine adenomyosis, etc. It is not used for the treatment of gynecological diseases based on the growth of ectopic endometrial tissue.
- An object of the present invention is to provide a therapeutic drug for estrogen-dependent gynecological diseases such as endometriosis, uterine fibroids, adenomyosis.
- a compound represented by the following structural formula (a) synthesized and clinically studied for the purpose of treating breast cancer is an estrogen receptor ⁇ -inhibiting ⁇ It has been found that it functions as a partial agonist and has an excellent therapeutic effect on gynecological diseases dependent on estrogen, and the present invention has been completed.
- the present invention provides the following specific embodiments (1) to (3).
- An estrogen receptor ⁇ -inhibiting ⁇ partial agonist represented by the following structural formula (a).
- a therapeutic agent for gynecological diseases comprising the estrogen receptor ⁇ -inhibiting ⁇ partial agonist according to (1) above, a pharmaceutically acceptable salt thereof, or a hydrate thereof as an active ingredient.
- the present invention also provides the following specific embodiments (4) to (8).
- An estrogen receptor ⁇ -inhibiting ⁇ partial agonist according to (1), a pharmaceutically acceptable salt thereof, or a hydrate thereof is administered as an active ingredient.
- a gynecological disease characterized by administering the estrogen receptor ⁇ -inhibiting ⁇ partial agonist according to (1) above, a pharmaceutically acceptable salt thereof, or a hydrate thereof as an active ingredient.
- a drug for treating estrogen-dependent gynecological diseases such as endometriosis, uterine fibroids, adenomyosis can be provided.
- the compound represented by the following structural formula (a) used in the present invention is orally active and has an estrogen receptor ⁇ inhibitory action and an estrogen receptor ⁇ partial agonist action.
- the compound represented by the structural formula (a) used in the present invention can be used as a free form, a pharmaceutically acceptable salt, or a hydrate thereof.
- the pharmaceutically acceptable salt is not particularly limited, but is an inorganic acid salt such as hydrochloride, sulfate, nitrate, hydrobromide, phosphate, etc .; acetate, trifluoroacetate, lactate, propion Acid, tartrate, glycolate, pyruvate, oxalate, malate, malonate, succinate, maleate, fumarate, tartrate, citrate, benzoate, silica
- organic acid salts such as cinnamate, mandelate, methanesulfonate, ethanesulfonate, p-toluenesulfonate, and salicylate.
- organic acid salts are preferable, and more preferable.
- Citrate, fumarate, succinate, benzoate, malonate, and more preferably citrate hereinafter, the citrate of the compound may be abbreviated as “SR16234”).
- the compound represented by the structural formula (a) used in the present invention, a pharmaceutically acceptable salt thereof, or a hydrate thereof can be produced, for example, according to the methods described in Patent Documents 1 and 2. it can.
- the compound represented by the structural formula (a), a pharmaceutically acceptable salt thereof, and a hydrate thereof suppress the growth of ectopic endometrial tissue, as shown in Examples described later.
- the growth inhibitory action is stable for a long time.
- it can be administered orally, has low toxicity, and can be used safely even in premenopausal patients. Therefore, the medicament of the present invention is particularly useful as a therapeutic agent for estrogen-dependent gynecological diseases such as endometriosis, uterine fibroids, adenomyosis.
- the therapeutic agent for gynecological diseases of the present invention contains at least the compound represented by the structural formula (a), a pharmaceutically acceptable salt thereof, or a hydrate thereof as an active ingredient.
- the therapeutic agent for gynecological diseases of the present invention may contain other components as necessary. Other components include, but are not limited to, stabilizers, surfactants, plasticizers, lubricants, solubilizers, buffers, sweeteners, base materials, adsorbents, corrigents, binders, suspending agents.
- Agents antioxidants, brighteners, coating agents, flavoring agents, fragrances, wetting agents, wetting regulators, antifoaming agents, chewing agents, cooling agents, coloring agents, sugar-coating agents, tonicity agents, pH adjustment Agent, softener, emulsifier, adhesive, adhesion enhancer, thickener, thickener, foaming agent, excipient, dispersant, propellant, disintegrant, disintegration aid, fragrance, moisture-proofing agent, antiseptic And pharmaceutical additives such as agents, preservatives, soothing agents, solvents, solubilizers, solubilizers, fluidizing agents, and the like.
- the administration form of the therapeutic agent for gynecological diseases of the present invention may be appropriately selected depending on the age, weight, disease, symptom and degree of the patient, and is not particularly limited.
- tablets including sublingual tablets and orally disintegrating tablets
- Administration injection (subcutaneous injection, intravenous injection, intramuscular injection, intraperitoneal injection, etc.), suppository (including rectal suppository, vaginal suppository), inhalant, transdermal absorption agent, eye drop
- Parenteral administration such as nasal preparations and nasal drops.
- These may be controlled-release preparations such as immediate-release preparations and sustained-release preparations.
- oral administration by oral administration is preferable from the viewpoints of easy administration, easy compliance with medication, and easy cost reduction.
- oral preparation tablets, liquids and syrups are preferable, and tablets are more preferable.
- the dosage of the therapeutic agent for gynecological diseases of the present invention is appropriately determined according to the age, sex, weight, disease, symptom and degree of the patient. Although it is not particularly limited as long as it is a pharmaceutically effective amount, it is preferably in the range of 0.05 to 20 mg / kg body weight for oral preparations in terms of free form of the compound represented by the structural formula (a), more preferably 0. The range is from 06 to 18 mg / kg body weight, more preferably from 0.07 to 17 mg / kg body weight. For parenteral agents, the range is from 0.001 to 10 mg / kg body weight, more preferably from 0.002 to 9 mg / kg. Body weight, more preferably in the range of 0.003-8 mg / kg body weight.
- the therapeutic agent for gynecological diseases of the present invention can be administered once or divided into several times.
- the daily dose is usually 0.1 to 5000 mg / kg, and it is desirable to use a single dose or divided doses.
- additives known in the art can be blended, and methods known in the art, for example, methods described in the 16th revision Japanese Pharmacopoeia, etc. Can be applied.
- methods known in the art for example, methods described in the 16th revision Japanese Pharmacopoeia, etc.
- binders, disintegrants, lubricants, coloring agents, flavoring agents, flavoring agents, etc. can be added.
- coloring agents, flavoring agents, flavoring agents, etc. can be produced.
- active ingredients are solvents such as purified water and ethanol, solubilizers, suspending agents, tonicity agents, flavoring agents, buffering agents, stabilizers, flavoring agents.
- a liquid preparation, a syrup preparation, etc. can be manufactured by carrying out dispensing preparation etc. according to a conventional method.
- dispensing preparation etc. After adding, etc., a liquid preparation, a syrup preparation, etc. can be manufactured by carrying out dispensing preparation etc. according to a conventional method.
- a pH adjuster, buffer, stabilizer, isotonic agent, local anesthetic, etc. to the active ingredient, it is aseptically sealed in a container according to a conventional method.
- an injection for subcutaneous, intramuscular, intravenous injection or the like can be produced.
- a rectal suppository when preparing a rectal suppository, it can be formulated by adding excipients, surfactants and the like to the active ingredient, and then mixing and molding according to a conventional method.
- the active ingredient When preparing ointments such as pastes, creams and gels, the active ingredient is blended with bases such as white petrolatum and paraffin, stabilizers, wetting agents, preservatives such as methyl parahydroxybenzoate, What is necessary is just to mix according to a conventional method.
- bases such as white petrolatum and paraffin, stabilizers, wetting agents, preservatives such as methyl parahydroxybenzoate, What is necessary is just to mix according to a conventional method.
- the ointment, cream, gel, paste or the like may be applied to a support such as a woven fabric, a nonwoven fabric, or a plastic film by a conventional method.
- the therapeutic agent for gynecological diseases of the present invention is intended for estrogen-dependent gynecological diseases.
- it since it has an action of suppressing the growth of ectopic endometrial tissue, it is preferable to target endometriosis, uterine fibroids, and uterine adenomyosis. Even previous patients can be used safely.
- symptoms such as excessive menstruation, irregular organ bleeding, dysmenorrhea, and compression symptoms caused by these diseases can be alleviated or treated.
- E2 treatment ( ⁇ -Estradiol, 3 ⁇ g / mL / animal) was administered daily subcutaneously on the back of the rats for 2 weeks after ovariectomy on the day of ovariectomy.
- E2 (3 ⁇ g / mL ⁇ animal) was administered in the same manner for 4 weeks after the model was created on the model creation date.
- Model preparation method On the next day after grouping, models were prepared according to the method of Uchiide et al., Which was partially modified from the method of Vernon et al. The rats were placed under inhalation anesthesia with 2% isoflurane, the abdomen was opened along the midline, and the right uterine horn was excised and removed, and the uterine horn adipose tissue was removed and divided into two equal parts along the vertical axis. An incision is made along the horizontal axis of the uterine horn, and two sections of about 5 mm ⁇ 5 mm are cut out.
- the excised uterine sections were combined with the serosa surface and endometrial surface of the abdominal cavity, the four corners were sutured with absorbent thread (6-0, PDS-II, Ethicon), and one uterine section was transplanted to each of the left and right abdominal walls. .
- absorbent thread 6-0, PDS-II, Ethicon
- one uterine section was transplanted to each of the left and right abdominal walls.
- physiological saline Otsuka Pharmaceutical Factory
- the abdominal wall fascia was sutured with an absorbent thread (4-0, monocryl, ethicon), and the skin was sutured with silk thread (4-0, blade silk, harmonyon).
- Plasma (2 mL or more) was obtained by centrifuging the collected EDTA-added blood under the conditions of 4 ° C., 1800 ⁇ g, 10 minutes. The collected plasma was stored frozen in an ultra-low temperature freezer.
- Preparation method stock solution for administration
- SR16234 was weighed and pulverized using an agate mortar and pestle, and then suspended in a 0.5% aqueous solution of sodium carboxymethylcellulose (CMC-Na) to prepare a 2 mg / mL solution, which was used as the dosing stock solution.
- CMC-Na sodium carboxymethylcellulose
- the preparation was performed using a volumetric flask.
- the obtained dosing stock solution was stored in a refrigerator (allowable range: 1 to 15 ° C.) in the refrigerator of the test substance storage room J009 after preparation, and used within 7 days with the preparation date being 0 days. The remaining dosing solution was discarded.
- Preparation method (administration solution)
- the dosing stock solution (2 mg / mL solution) was serially diluted with 0.5% CMC-Na aqueous solution to prepare 0.2, 0.06 and 0.02 mg / mL solutions, respectively.
- 0.5% CMC-Na aqueous solution was used as the administration solution for the vehicle control group.
- the preparation was performed using a graduated cylinder or a graduated flask. The remaining dosing solution was discarded.
- [3] Administration of drug The administration route was oral administration, and the drug was forcibly and continuously administered for 28 days in the stomach at a frequency of once / day using a flexible oral sonde and syringe.
- RNA later solution Treatment of isolated organs The pituitary gland, adrenal gland (right), transplanted uterine piece (1 piece), left uterine horn (collecting part of the above organs), and mammary gland (diameter of about 3 mm) were immersed in RNA later solution. Then, after refrigerated storage for 1 day, the RNA later solution was removed and stored in an ultra-low temperature freezer (RNA measurement sample). The remainder of the adrenal gland (right) was discarded, and the remainder of the adrenal gland (left), mammary gland (1) and each organ was frozen in liquid nitrogen and stored frozen in an ultra-low temperature freezer.
- Suppression rate of transplanted uterine weight (%) (average value of wet weight of transplanted uterine piece of vehicle control group ⁇ wet weight of transplanted uterine piece of each individual) ⁇ 100 / (wet weight of transplanted uterine piece of vehicle control group) Average value)
- Suppression rate of transplanted uterine section weight SR16234 when the suppression rate of transplanted uterine piece weight of the vehicle control group in which 0.5 w / v% aqueous carboxymethylcellulose sodium solution (0.5% CMC-Na aqueous solution) was orally administered for 28 days was 0%
- the suppression rate (average value) of the weight of transplanted uterine pieces in the 0.1, 0.3, and 1.0 mg / kg groups was calculated, they were 26%, 45%, and 68%, respectively.
- the rate of increase in the weight of transplanted uterine fragments in the SR16234 administration group increases with increasing dose.
- the 1.0 mg / kg administration group shows a significantly significant suppression rate of the transplanted uterine piece weight as compared with the vehicle control group. From the above, the improvement effect of endometriosis by the therapeutic agent for gynecological diseases of the present invention was confirmed.
- E2 ⁇ -Estradiol
- rats maintained hormone balance, and the right uterine horn was transplanted to the left and right abdominal walls.
- SR16234 was administered by oral administration once a day for 28 days from the date of creation of the endometriosis model by setting three doses of 0.1, 0.3 and 1.0 mg / kg.
- the total wet weight of the transplanted uterine pieces (including the abdominal wall) in the SR16234 administration group decreases as the dose increases.
- the 1.0 mg / kg administration group shows a particularly significant inhibition rate compared to the vehicle control group.
- Vehicle control group The wet weights of the pituitary, adrenal (left), adrenal (right), adrenal (left and right), left uterine horn, and femur (left) of the vehicle control group were 0.0271 g and 0, respectively. 0.0468 g, 0.0425 g, 0.0893 g, 0.1428 g, and 0.7589 g.
- SR16234 0.1 mg / kg administration group
- SR16234 0.1 mg / kg administration group
- SR16234 0.3 mg / kg administration group
- SR16234 0.3 mg / kg administration group
- SR16234 1.0 mg / kg administration group
- SR16234 1.0 mg / kg administration group
- RNA extraction reagent > ⁇ RNeasy Fibrous Tissue Mini Kit (QIAGEN) ⁇ Reverse transcriptase> ⁇ SuperScript VILO Master Mix (Life Technologies) ⁇ TaqMan Reagent> ⁇ TaqMan Gene Express Assay (Life Technologies)
- Test execution method Total RNA extraction RNA extraction was performed on rat-derived uterine horn slices and transplanted uterine pieces using the RNeasy Fibrous Tissue Mini Kit.
- RNA quality test using spectrophotometer and bioanalyzer Concentration measurement was performed on the extracted RNA using Nanodrop.
- RIN measurement using a bioanalyzer (6000 nano kit) was performed.
- a 6000 pico kit was used for bioanalyzer measurement of two specimens (Sample ID: 202,507) with low yield.
- Reverse Transcription Reaction (A) Standard Substance Commercially available Rat Tissue Universal Reference Total RNA (Catalog Number: PR-UR-100, ZYAGEN) 1000 ng / uL obtained from Superscript VILO Master Mix by reverse transcription standard using SuperScript VILO Master Mix ) was used as a standard substance. (B) Specimen A reverse transcription reaction of the specimen by Super Script VILO Master Mix was performed so that 50 ng / uL of cDNA (hereinafter referred to as a sample) was obtained based on the concentration measurement result by the spectrophotometer. For sample IDs 202, 502, and 507 with low yields, reverse transcription reactions were performed so that 25 ng / uL, 25 ng / uL, and 12.5 ng / uL of cDNA were obtained, respectively.
- TaqMan reaction A standard 250, 62.5, 15.625, 3.9, 0.98 ng / well or a sample of 5.0 ng / well was used, and a TaqMan reaction was performed using a Step One Plus Real-Time PCR System. The reaction was carried out at 50 ° C. for 2 minutes and at 95 ° C. for 10 minutes, followed by 40 cycles of reaction at 95 ° C. for 15 seconds and 60 ° C. for 1 minute. After the reaction at 60 ° C., the fluorescence value FAM was measured in real time. In addition to the eight target genes, the GAPDH gene was measured as an endogenous control gene. All standards and samples were measured with Triplicate.
- SR16234 had no effect on Era / Erb estrogen receptor gene expression, and showed a slightly increasing tendency for PR.
- VEGF gene involved in the promotion of angiogenesis as shown in FIG. 2, the gene expression of PEDF, an angiogenesis inhibitor, showed an increasing tendency.
- FIG. 3 the gene expression of IL-6, which is a cytokine involved in inflammation, was suppressed in a dose-dependent manner.
- the estrogen receptor ⁇ -inhibiting ⁇ partial agonist of the present invention can be administered orally, has low toxicity, and has an ectopic endometrial growth inhibitory action excellent in safety. It can be used widely and effectively as a drug for gynecological diseases dependent on estrogen such as adenomyosis.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
(1)下記構造式(a)で表される、エストロゲン受容体α阻害βパーシャルアゴニスト。
(4)上記(1)に記載のエストロゲン受容体α阻害βパーシャルアゴニスト、その薬学的に許容される塩、またはそれらの水和物を有効成分として投与することを特徴とする、婦人科疾患の治療方法;子宮内膜症、子宮筋腫、及び/又は子宮腺筋症の治療方法;並びに、閉経前患者の子宮内膜症、子宮筋腫、及び/又は子宮腺筋症の治療方法。
(5)上記(1)に記載のエストロゲン受容体α阻害βパーシャルアゴニスト、その薬学的に許容される塩、またはそれらの水和物を有効成分として投与することを特徴とする、婦人科疾患の軽減方法;子宮内膜症、子宮筋腫、及び/又は子宮腺筋症の軽減方法;並びに、閉経前患者の子宮内膜症、子宮筋腫、及び/又は子宮腺筋症の軽減方法。
(6)婦人科疾患の治療のための;子宮内膜症、子宮筋腫、及び/又は子宮腺筋症の治療のための;並びに、閉経前患者の子宮内膜症、子宮筋腫、及び/又は子宮腺筋症の治療のための、上記(1)に記載のエストロゲン受容体α阻害βパーシャルアゴニスト、その薬学的に許容される塩、又はそれらの水和物の使用。
(7)婦人科疾患の治療用薬剤の製造のための;子宮内膜症、子宮筋腫、及び/又は子宮腺筋症の治療用薬剤の製造のための;並びに、閉経前患者の子宮内膜症、子宮筋腫、及び/又は子宮腺筋症の治療用薬剤の製造のための、上記(1)に記載のエストロゲン受容体α阻害βパーシャルアゴニスト、その薬学的に許容される塩、またはそれらの水和物の使用。
(8)上記(1)及び(2)に記載のエストロゲン受容体α阻害βパーシャルアゴニストを有効成分として含有する種々の経口剤。
本発明で用いられる下記構造式(a)で表される化合物は、経口的に活性であり、エストロゲン受容体α阻害作用、及びエストロゲン受容体βパーシャルアゴニスト作用を有する。
本発明の婦人科疾患治療剤は、有効成分として上記構造式(a)で表される化合物、その薬学的に許容される塩、又はそれらの水和物を少なくとも含有する。本発明の婦人科疾患治療剤は、必要に応じてその他の成分を含有していてもよい。その他の成分としては、特に限定されないが、安定剤、界面活性剤、可塑剤、滑沢剤、可溶化剤、緩衝剤、甘味剤、基材、吸着剤、矯味剤、結合剤、懸濁化剤、抗酸化剤、光沢化剤、コーティング剤、着香剤、香料、湿潤剤、湿潤調整剤、消泡剤、咀嚼剤、清涼化剤、着色剤、糖衣剤、等張化剤、pH調節剤、軟化剤、乳化剤、粘着剤、粘着増強剤、粘稠剤、粘稠化剤、発泡剤、賦形剤、分散剤、噴射剤、崩壊剤、崩壊補助剤、芳香剤、防湿剤、防腐剤、保存剤、無痛化剤、溶剤、溶解剤、溶解補助剤、流動化剤等の医薬品添加剤が挙げられる。
<子宮内膜症モデルの作製>
[1]卵巣摘出
1.鎮痛剤処置
塩酸ブプレノルフィン(レペタン注0.3mg,大塚製薬株式会社,0.2mg/mL液を用時に生理食塩液で6.7倍に希釈して、0.03mg/mL液としたもの)を、0.0024mg/body(0.08mL/body)の投与量でラットの背部皮下に投与した。投与期間は、モデル作製日のモデル作製前後の2回及び作製翌日の1日2回の、2日間とした。なお、0.0024mg/bodyの投与量は、体重250g(モデル作製時の推定体重:180~240g)のラットにおいて、推奨用量の0.01mg/kgを満たしたものである(0.0096mg/kg)。
イソフルランの2%吸入麻酔下で、ラットの左右の腹側部(術部)を刈毛し、一方の腹側部の皮膚を切開した。筋層を剥離した後、開創器を用いて筋層を広げ、卵巣の周りの脂肪組織を含めて体外に突出させ、輸卵管の部位を絹糸(滅菌済みの縫合糸)で結紮後、脂肪組織を含めて卵巣を摘出した。剥離した筋層及び腹膜の一ヵ所を絹糸(滅菌済みの縫合糸)で縫合し、抗生物質であるカナマイシン液(Meiji Seikaファルマ株式会社,硫酸カナマイシン注射液1000mg「明治」を注射用水で5mg/mLに希釈したもの)を術部に添加した。切開した皮膚は絹糸(滅菌済みの縫合糸)で縫合した。また、反対側の卵巣も同様にして摘出した。なお、施術時には、滅菌手袋を使用し、手術器具はオートクレーブ及びビーズ滅菌器にて滅菌したものを使用した。術野は電気バリカンで刈毛後、イソジンアルコールで消毒し、滅菌敷布及び覆布で覆った。
卵巣摘出日の卵巣摘出後から2週間、ラットの背部皮下にE2(β-Estradiol、3μg/mL・匹)を毎日投与した。また,モデル作製日のモデル作製後から4週間、E2(3μg/mL・匹)を同様に投与した。
1.群分け
卵巣摘出日(0日起算)から13日後に、群分け日の体重が各群で均一になるように,4群(N=8)に振り分けた。また,群分け除外した動物は、全例をSham群に振り分けた。
群分けの翌日に、Vernonらの方法を一部改変したUchiideらの方法に従って、モデル作製を行った。ラットを2%イソフルランの吸入麻酔下におき、腹部を正中線に沿って開腹し、右側の子宮角を摘出し摘出した子宮角の脂肪組織を除き,縦軸に沿って2等分した。子宮角を横軸に沿って切開し、約5mm×5mmの切片2個を切り出す。切り出した子宮切片は、腹腔の漿膜面と子宮内膜面を合わせ、四隅を吸収糸(6-0,PDS-II,エチコン)で縫合し、左右の腹壁に各1個の子宮切片を移植した。腹腔内の癒着防止のため、生理食塩液(株式会社大塚製薬工場)で洗浄した。その後、腹壁筋膜を吸収糸(4-0,モノクリル,エチコン)で縫合し、皮膚を絹糸(4-0,ブレードシルク,エチコン)で縫合した。
1.解剖
モデル作製日の前日(群分け日)に、2%イソフルランの吸入麻酔下で,腹部を切開した。次に、腹部大静脈から注射筒で約5mLを採血し、血液5mLをベノジェクトII真空採血管(EDTA-2K)に採取し、採取後、腹部大動脈及び腹部大静脈を切開して放血致死させた。次いで、右子宮角を摘出して切片(約5mm×5mm)を2個作製し、移植部位にあたる左右の腹壁(筋層及び腹膜)から切片(約5mm×5mm)を摘出した。その後、それぞれの切片及び腹壁の湿重量を測定した。次に、下垂体、副腎(両側)、左子宮角、乳腺(乳頭を含めて摘出,下腹部の3個,但しRNA測定用サンプルは直径約3mmとした。)及び大腿骨(左側)を摘出した。
採取したEDTA加血液を4℃,1800×g,10分間の条件で遠心することで、血漿(2mL以上)を得た。採取した血漿は、超低温フリーザーに冷凍保存した。
下垂体、副腎(両側)、左子宮角及び大腿骨については、湿重量を測定した。なお,湿重量測定後の大腿骨は廃棄した。
下垂体、副腎(右)、子宮角切片(約5mm×5mm)及び移植部位にあたる腹壁(筋層及び腹膜,約5mm×5mm)(各1個)、左子宮角(以上の臓器の一部を採取)、乳腺(直径約3mm)をRNA later液にそれぞれ浸漬し、1日冷蔵保存した後、RNA later液を除去して、超低温フリーザーに保存した(RNA測定用サンプル)。副腎(右)の残余は廃棄し、副腎(左)、乳腺(1個)及び各臓器の残余は,液体窒素で凍結した。
乳腺及び残りの子宮角切片(約5mm×5mm)並びに移植部位にあたる腹壁(筋層及び腹膜,約5mm×5mm)(各1個)は、それぞれ10%中性緩衝ホルマリン液に浸漬固定し、パラフィンブロック包埋標本を作製した。
[1]調製方法(投与原液)
必要量のSR16234を秤量し、メノウ製の乳鉢及び乳棒を用いて粉砕した後、0.5%カルボキシメチルセルロースナトリウム(CMC-Na)水溶液に懸濁して2mg/mL液を調製し、投与原液とした。調製は,メスフラスコを用いて行った。得られた投与原液は、調製後に被験物質保管室J009の冷蔵庫に冷所(許容範囲:1~15°C)保存し、調製日を0日として7日以内に使用した。なお、残余の投与原液は廃棄した。
投与原液(2mg/mL液)を0.5%CMC-Na水溶液で段階希釈して、0.2,0.06及び0.02mg/mL液をそれぞれ調製した。また、媒体対照群の投与液としては、0.5%CMC-Na水溶液を用いた。調製は、メスシリンダー或いはメスフラスコを用いて行った。なお、残余の投与原液は廃棄した。
投与経路は経口投与とし、フレキシブル経口ゾンデ及び注射筒を用いて、1回/日の頻度で胃内に強制的に28日間連続投与した。
[1]解剖
最終投与の翌日に、2%イソフルランの吸入麻酔下で、腹部を切開し、移植子宮片(2個)を摘出し、デジタルカメラで撮影した。次に、腹部大静脈から注射筒で約5mLを採
血し、血液5mLをベノジェクトII真空採血管(EDTA-2K)に採取し、採取後、腹部大動脈及び腹部大静脈を切開して放血致死させた。次に、下垂体、副腎(両側)、移植子宮片(2個)、左子宮角、乳腺(乳頭を含めて摘出,下腹部の3個,但しRNA測定用サンプルは直径約3mmとした。)及び大腿骨(左側)を摘出した。
移植子宮片は,定規を添えて、1個ごとデジタルカメラで撮影した。
採取したEDTA加血液を4℃,1800×g,10分間の条件で遠心することで、血漿(2mL以上)を得た。採取した血漿は,超低温フリーザーに冷凍保存した。
下垂体、副腎(両側)、移植子宮片(2個)、左子宮角及び大腿骨については湿重量を測定した。なお、湿重量測定後の大腿骨は廃棄した。
下垂体、副腎(右)、移植子宮片(1個)、左子宮角(以上の臓器の一部を採取)、乳腺(直径約3mm)をRNA later液にそれぞれ浸漬し、1日冷蔵保存した後、RNA later液を除去して,超低温フリーザーに保存した(RNA測定用サンプル)。副腎(右)の残余は廃棄し、副腎(左)、乳腺(1個)及び各臓器の残余は、液体窒素で凍結し、超低温フリーザーに冷凍保存した。
乳腺及び残りの移植子宮片(1個)は、10%中性緩衝ホルマリン液に浸漬固定し、パラフィンブロック包埋標本を作製した。
1.移植子宮片の湿重量の算出
各移植子宮片の湿重量(左右)は、Sham群の左右の腹壁の湿重量の平均値をそれぞれ差し引いて算出した。
移植子宮片重量の抑制率は、左右の移植子宮片の湿重量の合計の平均値に基づいて算出した。ここでは、媒体対照群の移植子宮片の湿重量の平均値を基準とし、媒体対照群及び被験物質群の移植子宮片重量の抑制率(%)を、下式に基づいて算出した。表1に、算出結果を示す。
移植子宮片重量の抑制率(%)=(媒体対照群の移植子宮片の湿重量の平均値-各個体の移植子宮片の湿重量)×100/(媒体対照群の移植子宮片の湿重量の平均値)
0.5w/v%カルボキシメチルセルロースナトリウム水溶液(0.5%CMC-Na水溶液)を28日間経口投与した媒体対照群の移植子宮片重量の抑制率を0%として、SR16234の0.1、0.3及び1.0mg/kg群の移植子宮片重量の抑制率(平均値)を算出したところ、それぞれ26%、45%、及び68%であった。
<移植子宮片及び腹壁の湿重量の合計>
Sham群の左右の子宮切片及び腹壁の湿重量の合計は、0.2596gであった。また、媒体対照群、SR16234の0.1、0.3及び1.0mg/kg群の左右の移植子宮片(腹壁を含む)の湿重量の合計は、それぞれ0.4785g、0.3988g、0.3401g及び0.2647gであった。
<各臓器の湿重量>
[1]Sham群
Sham群の下垂体、副腎(左)、副腎(右)、副腎(左右の合計)、左子宮角及び大腿骨(左側)の湿重量は、それぞれ0.0186g、0.0353g、0.0296g、0.0649g、0.1751g、及び0.7083gであった。
媒体対照群の下垂体、副腎(左)、副腎(右)、副腎(左右の合計)、左子宮角及び大腿骨(左側)の湿重量は、それぞれ0.0271g、0.0468g、0.0425g、0.0893g、0.1428g、及び0.7589gであった。
SR16234の0.1mg/kg投与群の下垂体、副腎(左)、副腎(右)、副腎(左右の合計)、左子宮角及び大腿骨(左側)の湿重量は、それぞれ0.0226g、0.0438g、0.0400g、0.0838g、0.1261g、及び0.7597gであった。
SR16234の0.3mg/kg投与群の下垂体、副腎(左)、副腎(右)、副腎(左右の合計)、左子宮角及び大腿骨(左側)の湿重量は、それぞれ0.0187g、0.0398g、0.0381g、0.0779g、0.1119g、及び0.7598gであった。
SR16234の1.0mg/kg投与群の下垂体、副腎(左)、副腎(右)、副腎(左右の合計)、左子宮角及び大腿骨(左側)の湿重量は、それぞれ0.0174g、0.0375g、0.0357g、0.0732g、0.1016g、及び0.7301gであった。
いずれの湿重量においても、SR16234投与群は、媒体対照群と比較して用量の増加に伴った減少傾向を示すことが確認された。また、SR16234の0.3及び1.0mg/kg投与群は、媒体対照群と比較して、Day14以降において、極軽度ではあるが体重抑制傾向を示すことが確認された。
<子宮内膜移植片の遺伝子発現解析>
[1]要約
ラット由来子宮内膜移植片(27検体)8ターゲット遺伝子について、総RNAの抽出後、分光光度計およびバイオアナライザによるRNAの品質検査を行った後、RNAの逆転写反応を行い、TaqMan法により遺伝子発現解析を行った。
・NanoDrop 1000(Thermo Fisher Scientific製)
・Agilent 2100バイオアナライザ(Agilent製)
・Step One Plus Real-Time PCR System (Life Technologics製)
<RNA抽出試薬>
・RNeasy Fibrous Tissue Mini Kit (QIAGEN)
<逆転写酵素>
・SuperScript VILO Master Mix (Life Technologies)
<TaqMan試薬>
・TaqMan Gene Express Assay (Life Technologies)
1.総RNA抽出
ラット由来子宮角切片および移植子宮片について、RNeasy Fibrous Tissue Mini Kitを用いてRNA抽出を行った。
抽出後のRNAについてNanaoDropによる濃度測定を行った。また、バイオアナライザ(6000ナノキット)によるRIN測定を実施した。なお、収量が少ない2検体(Sample ID:202,507)のバイオアナライザ測定には6000ピコキットを用いた。
(A)標準物質
市販Rat Tissue Universal Reference Total RNA (Catalog Number:PR-UR-100, ZYAGEN社)1000ng/uLからSuperScript VILO Master Mixによる逆転写反応により得られたcDNA(以下スタンダードとする)を標準物質として用いた。
(B)検体
分光光度計による濃度測定結果を基に、50ng/uLのcDNA(以下サンプルとする)が得られるよう、Super Script VILO Master Mixによる検体の逆転写反応を行った。なお収量が少ないSample ID:202,502,507に関しては、それぞれ25ng/uL,25ng/uL,12.5ng/uLのcDNAが得られるように逆転写反応を行った。
スタンダード250,62.5,15.625,3.9,0.98ng/wellまたはサンプル5.0ng/wellを使用し、Step One Plus Real-Time PCR Systemを用いてTaqMan反応を行った。反応は50℃で2分間、および95℃で10分間反応後、95℃で15秒間,60℃で1分間の反応を40サイクル行い、60℃での反応後に蛍光値FAMをリアルタイムに測定した。また、ターゲット遺伝子8種類に加え、内在性コントロール遺伝子としてGAPDH遺伝子を測定した。なお、全てのスタンダード、サンプルはTriplicateで測定した。
スタンダードから得られた2種の検量線(ターゲット遺伝子、GAPDH遺伝子)それぞれから、サンプルに関するターゲット遺伝子、GAPDH遺伝子の発現量をそれぞれ算出した。その後、内在性コントロール遺伝子であるGAPDH遺伝子発現量により、ターゲット遺伝子の発現量を補正した。さらにサンプルにおいて発現量の各群平均値を算出した後、2群の発現量平均値を標準として、その他各群と比較した。
Claims (3)
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16824495.2A EP3323417A4 (en) | 2015-07-14 | 2016-07-13 | PARTIAL ESTROGEN RECEPTOR BETA AGONIST WITH ESTROGEN RECEPTOR-ALPHA-INHIBITING EFFECT AND THERAPEUTIC AGENT AGAINST GYNECOLOGICAL DISORDERS THEREOF |
JP2017528707A JPWO2017010515A1 (ja) | 2015-07-14 | 2016-07-13 | エストロゲン受容体α阻害作用を有するエストロゲン受容体βパーシャルアゴニスト及びこれを用いた婦人科疾患治療剤 |
CA2992407A CA2992407A1 (en) | 2015-07-14 | 2016-07-13 | Estrogen receptor .beta. partial agonist having estrogen receptor .alpha. inhibitory effect, and gynecological disease therapeutic agent using same |
US15/744,537 US20180200266A1 (en) | 2015-07-14 | 2016-07-13 | ESTROGEN RECEPTOR Beta PARTIAL AGONIST HAVING ESTROGEN RECEPTOR Alpha INHIBITORY EFFECT, AND GYNECOLOGICAL DISEASE THERAPEUTIC AGENT USING SAME |
AU2016294185A AU2016294185B2 (en) | 2015-07-14 | 2016-07-13 | Estrogen receptor β partial agonist having estrogen receptor α inhibitory effect, and therapeutic agent for gynecological disorders using same |
CN201680053270.6A CN108348531A (zh) | 2015-07-14 | 2016-07-13 | 具有雌激素受体α抑制作用的雌激素受体β部分激动剂及使用该雌激素受体β部分激动剂的妇科疾病治疗剂 |
KR1020187004505A KR20180059427A (ko) | 2015-07-14 | 2016-07-13 | 에스트로겐 수용체 α 저해 작용을 갖는 에스트로겐 수용체 β 부분 아고니스트 및 이를 사용한 부인과 질환 치료제 |
US16/138,556 US10369159B2 (en) | 2015-07-14 | 2018-09-21 | Estrogen receptor β partial agonist having estrogen receptor α inhibitory effect, and gynecological disease therapeutic agent using same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015-140620 | 2015-07-14 | ||
JP2015140620 | 2015-07-14 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/744,537 A-371-Of-International US20180200266A1 (en) | 2015-07-14 | 2016-07-13 | ESTROGEN RECEPTOR Beta PARTIAL AGONIST HAVING ESTROGEN RECEPTOR Alpha INHIBITORY EFFECT, AND GYNECOLOGICAL DISEASE THERAPEUTIC AGENT USING SAME |
US16/138,556 Continuation US10369159B2 (en) | 2015-07-14 | 2018-09-21 | Estrogen receptor β partial agonist having estrogen receptor α inhibitory effect, and gynecological disease therapeutic agent using same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017010515A1 true WO2017010515A1 (ja) | 2017-01-19 |
Family
ID=57757169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/070687 WO2017010515A1 (ja) | 2015-07-14 | 2016-07-13 | エストロゲン受容体α阻害作用を有するエストロゲン受容体βパーシャルアゴニスト及びこれを用いた婦人科疾患治療剤 |
Country Status (8)
Country | Link |
---|---|
US (2) | US20180200266A1 (ja) |
EP (1) | EP3323417A4 (ja) |
JP (1) | JPWO2017010515A1 (ja) |
KR (1) | KR20180059427A (ja) |
CN (1) | CN108348531A (ja) |
AU (1) | AU2016294185B2 (ja) |
CA (1) | CA2992407A1 (ja) |
WO (1) | WO2017010515A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018212256A1 (ja) * | 2017-05-16 | 2018-11-22 | ノーベルファーマ株式会社 | エストロゲン受容体α阻害作用を有するエストロゲン受容体βパーシャルアゴニストを用いた、子宮内膜症、子宮腺筋症等の婦人科疾患の疼痛、及び/又は器質的病変の治療剤 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113069496B (zh) * | 2021-03-18 | 2022-09-06 | 济川药业集团有限公司 | 用于治疗小儿感冒的中药颗粒组合物及制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010054758A1 (en) * | 2008-11-11 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | Synergistic pharmaceutical combination comprising an estrogen receptor antagonist and a progestin |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6054446A (en) | 1997-12-24 | 2000-04-25 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
US6503896B1 (en) * | 1997-12-24 | 2003-01-07 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
WO2001058919A2 (en) | 2000-02-11 | 2001-08-16 | Sri International | Synthesis of anti-estrogenic and other therapeutic steroids from 21-hydroxy-19-norpregna-4-en-3-one |
CA2683809A1 (en) * | 2007-04-23 | 2008-10-30 | Bayer Schering Pharma Aktiengesellschaft | Progesterone-receptor antagonist for use in brca alone or as combination with antiestrogen |
WO2013131105A1 (en) * | 2012-03-02 | 2013-09-06 | Sri International | Synergistic anti-proliferation activity of tas-108 with mtor inhibitors against cancer cells |
-
2016
- 2016-07-13 KR KR1020187004505A patent/KR20180059427A/ko unknown
- 2016-07-13 EP EP16824495.2A patent/EP3323417A4/en not_active Withdrawn
- 2016-07-13 US US15/744,537 patent/US20180200266A1/en not_active Abandoned
- 2016-07-13 CN CN201680053270.6A patent/CN108348531A/zh active Pending
- 2016-07-13 JP JP2017528707A patent/JPWO2017010515A1/ja active Pending
- 2016-07-13 CA CA2992407A patent/CA2992407A1/en not_active Abandoned
- 2016-07-13 AU AU2016294185A patent/AU2016294185B2/en active Active
- 2016-07-13 WO PCT/JP2016/070687 patent/WO2017010515A1/ja active Application Filing
-
2018
- 2018-09-21 US US16/138,556 patent/US10369159B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010054758A1 (en) * | 2008-11-11 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | Synergistic pharmaceutical combination comprising an estrogen receptor antagonist and a progestin |
Non-Patent Citations (6)
Title |
---|
CHUNG Y J. ET AL.: "The Effect of GnRH Agonist,Serm,Antiprogesterone in the Treatment of Uterine Myomas", ACTA OBSTETRICA ET GYNAECOLOGIA JAPONICA, vol. 65, no. 2, 2013, pages 994, XP055347270 * |
KULAK J JR. ET AL.: "Treatment with Bazedoxifene, a Selective Estrogen Receptor Modulator, Causes Regression of Endometriosis in a Mouse Model", ENDOCRINOLOGY, vol. 152, no. 8, 2011, pages 3226 - 3232, XP055347267 * |
MASAHIRO NOZAKI: "The effect of raloxifene on reproductive organs", OBSTETRICAL AND GYNECOLOGICAL THERAPY, vol. 94, no. 5, 2007, pages 967 - 972, XP009508381 * |
MINUTOLO F. ET AL.: "Estrogen Receptor beta Ligands: Recent Advances and Biomedical Applications", MEDICINAL RESEARCH REVIEWS, vol. 31, no. 3, 2011, pages 364 - 442, XP055347261 * |
See also references of EP3323417A4 * |
TANIGUCHI F. ET AL.: "SR-16234, a selective estrogen receptor modulator, represses development of endemetriosis-like lesions in rat model", ACTA OBSTETRICA ET GYNAECOLOGIA JAPONICA, vol. 68, no. 2, February 2016 (2016-02-01), pages 567, XP009508384 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018212256A1 (ja) * | 2017-05-16 | 2018-11-22 | ノーベルファーマ株式会社 | エストロゲン受容体α阻害作用を有するエストロゲン受容体βパーシャルアゴニストを用いた、子宮内膜症、子宮腺筋症等の婦人科疾患の疼痛、及び/又は器質的病変の治療剤 |
Also Published As
Publication number | Publication date |
---|---|
AU2016294185A1 (en) | 2018-03-01 |
CA2992407A1 (en) | 2017-01-19 |
US20190022111A1 (en) | 2019-01-24 |
JPWO2017010515A1 (ja) | 2018-07-05 |
US10369159B2 (en) | 2019-08-06 |
CN108348531A (zh) | 2018-07-31 |
US20180200266A1 (en) | 2018-07-19 |
EP3323417A4 (en) | 2019-06-05 |
EP3323417A1 (en) | 2018-05-23 |
KR20180059427A (ko) | 2018-06-04 |
AU2016294185B2 (en) | 2021-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2684565B1 (en) | Use of ulipristal acetate for treating uterine fibroids | |
EP2114412B1 (en) | Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method | |
TW201322986A (zh) | 18-甲基-6,7-亞甲基-3-氧基-17-妊-4-烯-21,17β-羧內酯、包含該化合物之醫療製劑及其於治療子宮內膜異位症之用途 | |
EA025582B1 (ru) | Интравагинальное кольцо, высвобождающее анастрозол и левоноргестрел для лечения эндометриоза | |
US20220143045A1 (en) | Progesterone receptor antagonist dosage form | |
US10369159B2 (en) | Estrogen receptor β partial agonist having estrogen receptor α inhibitory effect, and gynecological disease therapeutic agent using same | |
EP0654267B1 (en) | Carcinostatic for hormonotheraphy containing dienogest as effective component | |
JP2021518405A (ja) | プロゲステロン膣内デバイス | |
WO2018212256A1 (ja) | エストロゲン受容体α阻害作用を有するエストロゲン受容体βパーシャルアゴニストを用いた、子宮内膜症、子宮腺筋症等の婦人科疾患の疼痛、及び/又は器質的病変の治療剤 | |
CN116570593B (zh) | 一种防止卵巢早衰的药物及其用途 | |
JP3754466B2 (ja) | ジエノゲストを有効成分とするホルモン療法用制癌剤 | |
TW201803570A (zh) | 用於治療疾病之低劑量口服劑型 | |
NZ750686A (en) | Progesterone receptor antagonist dosage form | |
NZ712670B2 (en) | Progesterone receptor antagonist dosage form | |
NZ750686B2 (en) | Progesterone receptor antagonist dosage form |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16824495 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017528707 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2992407 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15744537 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20187004505 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016824495 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016294185 Country of ref document: AU Date of ref document: 20160713 Kind code of ref document: A |